← Research library / Longevity
FOXO4-DRI has never been tested in humans. Not in a Phase 1, not in a safety study, not anywhere. Everything known about it comes from cell culture and mice. It is being sold to people regardless.
Senescent cells are cells that have stopped dividing but do not die, accumulating with age and secreting inflammatory signals. Clearing them improves multiple measures of ageing in mice, and senolytics are a legitimate and active area of research.
FOXO4-DRI works by disrupting the interaction between FOXO4 and p53 in senescent cells, which releases p53 to trigger apoptosis. The design intent is that healthy cells are unaffected.
The 2017 study was real and the results were dramatic. That is precisely why caution is warranted rather than the opposite. A compound designed to trigger programmed cell death, with selectivity established only in mice, administered to a human with no dose-finding and no safety data, is not an experiment with a predictable downside.
Off-target apoptosis is the obvious concern, and nobody can tell you the human margin between the intended effect and that, because it has never been measured.
Full library · Safety and sourcing · Reconstitution calculator · The 2026 regulatory picture
Regulatory status current as of the page date. This area is changing quickly and this page is reviewed monthly.